Glenmark Pharmaceuticals Share Price
- Advice
- Hold
Start SIP in Glenmark Pharmaceuticals
Start SIPGlenmark Pharmaceuticals Performance
Day Range
- Low 1,730
- High 1,757
52 Week Range
- Low 722
- High 1,757
- Open Price1,745
- Previous Close1,748
- Volume696374
Glenmark Pharmaceuticals F&O
Glenmark Pharmaceuticals Investment Rating
-
Master Rating:
-
Glenmark Pharms. (Nse) has an operating revenue of Rs. 12,021.22 Cr. on a trailing 12-month basis. An annual revenue de-growth of -5% needs improvement, Pre-tax margin of 0% needs improvement, ROE of -19% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 14% and 57% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 33 which is a POOR score indicating inconsistency in earnings, a RS Rating of 85 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 55 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 2,297 | 2,148 | 1,365 | 2,233 | 2,144 | 1,875 |
| Operating Expenses Qtr Cr | 1,698 | 1,651 | 1,549 | 1,763 | 1,659 | 1,721 |
| Operating Profit Qtr Cr | 631 | 497 | -184 | 471 | 485 | 218 |
| Depreciation Qtr Cr | 53 | 52 | 51 | 50 | 49 | 47 |
| Interest Qtr Cr | 15 | 83 | 74 | 58 | 62 | 59 |
| Tax Qtr Cr | 165 | 1,681 | -55 | 87 | 120 | -176 |
| Net Profit Qtr Cr | 454 | 4,614 | -20 | 302 | 272 | -137 |
Glenmark Pharmaceuticals Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹1,676.70
- 50 Day
- ₹1,546.16
- 100 Day
- ₹1,385.28
- 200 Day
- ₹1,187.51
- 20 Day
- ₹1,698.97
- 50 Day
- ₹1,535.02
- 100 Day
- ₹1,331.81
- 200 Day
- ₹1,113.57
Glenmark Pharmaceuticals Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 1,763.58 |
| Second Resistance | 1,773.47 |
| Third Resistance | 1,790.43 |
| RSI | 76.04 |
| MFI | 55.84 |
| MACD Single Line | 66.81 |
| MACD | 61.64 |
| Support | |
|---|---|
| First Support | 1,736.73 |
| Second Support | 1,719.77 |
| Third Supoort | 1,709.88 |
Glenmark Pharmaceuticals Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 706,157 | 36,635,425 | 51.88 |
| Week | 939,267 | 50,964,606 | 54.26 |
| 1 Month | 1,262,862 | 55,565,909 | 44 |
| 6 Month | 961,243 | 41,121,960 | 42.78 |
Glenmark Pharmaceuticals Result Highlights
Glenmark Pharmaceuticals Synopsis
NSE-Medical-Generic Drugs
Glenmark Pharma is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 8220.66 Cr. and Equity Capital is Rs. 28.22 Cr. for the Year ended 31/03/2023. Glenmark Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 18/11/1977 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24299MH1977PLC019982 and registration number is 019982.| Market Cap | 49,487 |
| Sales | 8,076 |
| Shares in Float | 14.96 |
| No of funds | 285 |
| Yield | 0.14 |
| Book Value | 2.15 |
| U/D Vol ratio | 2.7 |
| LTDebt / Equity | 15 |
| Alpha | 0.19 |
| Beta | 1.01 |
Glenmark Pharmaceuticals Shareholding Pattern
| Owner Name | Jun-24 | Mar-24 | Dec-23 | Sep-23 |
|---|---|---|---|---|
| Promoters | 46.65% | 46.64% | 46.65% | 46.65% |
| Mutual Funds | 10.92% | 10.55% | 8.59% | 7.3% |
| Insurance Companies | 1.95% | 2.25% | 1.68% | 2.44% |
| Foreign Portfolio Investors | 20.98% | 21.38% | 23.71% | 24.79% |
| Financial Institutions/ Banks | 0.08% | 0.14% | 0.2% | 0.2% |
| Individual Investors | 14.58% | 14.83% | 14.78% | 14.84% |
| Others | 4.84% | 4.21% | 4.39% | 3.78% |
Glenmark Pharmaceuticals Management
| Name | Designation |
|---|---|
| Mr. Glenn Saldanha | Chairman & Managing Director |
| Mrs. Cherylann Pinto | Executive Director - Corporate Affairs |
| Mr. V S Mani | Executive Director & Global CFO |
| Mr. Rajesh V Desai | Ind. Non-Executive Director |
| Dr. Brian W Tempest | Ind. Non-Executive Director |
| Mr. Dipankar Bhattacharjee | Ind. Non-Executive Director |
| Mr. Bernard Munos | Ind. Non-Executive Director |
| Mr. Sridhar Gorthi | Ind. Non-Executive Director |
| Mrs. Vijayalakshmi Iyer | Ind. Non-Executive Director |
| Mr. D R Mehta | Ind. Non-Executive Director |
| Ms. Saira Ramasastry | Ind. Non-Executive Director |
| Mrs. B E Saldanha | Non Executive Director |
Glenmark Pharmaceuticals Forecast
Price Estimates
Glenmark Pharmaceuticals Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2024-08-14 | Quarterly Results | |
| 2024-05-24 | Audited Results & Final Dividend | |
| 2024-02-14 | Quarterly Results | |
| 2023-11-10 | Quarterly Results | |
| 2023-08-11 | Quarterly Results |
Glenmark Pharmaceuticals FAQs
What is Share Price of Glenmark Pharmaceuticals ?
Glenmark Pharmaceuticals share price is ₹1,753 As on 16 September, 2024 | 05:37
What is the Market Cap of Glenmark Pharmaceuticals ?
The Market Cap of Glenmark Pharmaceuticals is ₹49487.3 Cr As on 16 September, 2024 | 05:37
What is the P/E ratio of Glenmark Pharmaceuticals ?
The P/E ratio of Glenmark Pharmaceuticals is -37.7 As on 16 September, 2024 | 05:37
What is the PB ratio of Glenmark Pharmaceuticals ?
The PB ratio of Glenmark Pharmaceuticals is 6.3 As on 16 September, 2024 | 05:37